Fracture risk in older, long-term survivors of early-stage breast cancer
- PMID: 23647433
- PMCID: PMC3686911
- DOI: 10.1111/jgs.12269
Fracture risk in older, long-term survivors of early-stage breast cancer
Abstract
Objectives: To examine the effect of breast cancer and its treatment on fracture risk in older breast cancer survivors.
Design: A 10-year prospective cohort study beginning 5 years after a diagnosis of breast cancer for survivors and match date for comparison women.
Setting: Six integrated healthcare systems.
Participants: Women aged 65 and older (1,286 survivors, 1,286 comparison women, mean age 77.7 in both groups, white, non-Hispanic: survivors, 81.6%; comparison women, 85.2%) who were alive and recurrence free 5 years after a diagnosis of early-stage breast cancer and matched on age, study site, and enrollment year to a comparison cohort without breast cancer.
Measurements: Cox proportional hazards models were used to estimate the association between fracture risk and survivor-comparison status, adjusting for drugs and risk factors associated with bone health. A subanalysis was used to evaluate the association between tamoxifen exposure and fracture risk.
Results: No difference was observed in fracture rates between groups (hazard ratio (HR) = 1.1, 95% confidence interval (CI) = 0.9-1.3). The protective effect of tamoxifen was not statistically significant (HR = 0.9, 95% CI = 0.6-1.2).
Conclusion: Long-term survivors of early-stage breast cancer diagnosed at age 65 and older are not at greater risk of osteoporotic fractures than age-matched women without breast cancer. There appears to be no long-term protection from fractures with tamoxifen use.
© 2013, Copyright the Authors Journal compilation © 2013, The American Geriatrics Society.
Conflict of interest statement
The following conflicts of interest are reported for this study: Receipt of salary for work performed on grants and contracts funded by commercial entities including Novartis and the International Serious Adverse Event Consortium (Pawloski); GlaxoSmithKline, Astra Zenica, Novartis, Amgen, Pfizer, Merck, Sanofia Aventis and others (Petersen).
References
-
- Cancer survivors--United States, 2007. MMWR Morb Mort Wkly Rep. 2011;60:269–272. - PubMed
-
- Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–241. - PubMed
-
- van de Water W, Markopoulos C, van de Velde CJ, et al. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA. 2012;307:590–597. - PubMed
-
- American Cancer Society. [[cited March 9, 2012]];Cancer facts and figures. 2012 Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume....
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical